Piotr Radziszewski

List of Publications by Year
in descending order

74	575	840585 11	752573 20
papers	citations	h-index	g-index

108	108	108	882
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Neurogenic lower urinary tract dysfunction: Clinical management recommendations of the Neurologic Incontinence committee of the fifth International Consultation on Incontinence 2013. Neurourology and Urodynamics, 2016, 35, 657-665.	0.8	81
2	Neurogenic bowel dysfunction: Clinical management recommendations of the Neurologic Incontinence Committee of the Fifth International Consultation on Incontinence 2013. Neurourology and Urodynamics, 2018, 37, 46-53.	0.8	40
3	Fournierâ€™s Gangrene: Clinical Presentation of 13 Cases. Medical Science Monitor, 2018, 24, 548-555.	0.5	31
4	Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics. International Urology and Nephrology, 2019, 51, 1089-1099.	0.6	25
5	The Learning Curve for Transurethral Resection of Bladder Tumour: How Many is Enough to be Independent, Safe and Effective Surgeon?. Journal of Surgical Education, 2020, 77, 978-985.	1.2	25
6	Clinical rationale and safety of restaging transurethral resection in indication-stratified patients with high-risk non-muscle-invasive bladder cancer. World Journal of Surgical Oncology, 2018, 16, 6.	0.8	20
7	Intraurethral co-transplantation of bone marrow mesenchymal stem cells and muscle-derived cells improves the urethral closure. Stem Cell Research and Therapy, 2018, 9, 239.	2.4	19
8	Predicting stone composition before treatment â€“ can it really drive clinical decisions?. Central European Journal of Urology, 2014, 67, 392-6.	0.2	19
9	Predicting side-specific prostate cancer extracapsular extension: a simple decision rule of PSA, biopsy, and MRI parameters. International Urology and Nephrology, 2019, 51, 1545-1552.	0.6	18
10	Pressure-flow nomogram for women with lower urinary tract symptoms. Archives of Medical Science, 2014, 4, 752-756.	0.4	15
11	Impact of stage and comorbidities on five-year survival after radical cystectomy in Poland: single centre experience. Central European Journal of Urology, 2015, 68, 278-83.	0.2	14
12	MCM5 urine expression (ADXBLADDER) is a reliable biomarker of high-risk non- muscle-invasive bladder cancer recurrence: A prospective matched case-control study. Cancer Biomarkers, 2021, 30, 139-143.	0.8	13
13	The effect of O-1602, a GPR55 agonist, on the cyclophosphamide-induced rat hemorrhagic cystitis. European Journal of Pharmacology, 2020, 882, 173321.	1.7	11
14	Nephrogenic adenoma of the urinary bladder: A report of three cases and a review of the literature. Annals of Transplantation, 2014, 19, 153-156.	0.5	11
15	Expression of Toll-Like Receptors in the Animal Model of Bladder Outlet Obstruction. BioMed Research International, 2020, 2020, 1-11.	0.9	11
16	Innervation pattern of polycystic ovaries in the women. Journal of Chemical Neuroanatomy, 2014, 61-62, 147-152.	1.0	10
17	Expression of bone morphogenetic protein-2 and -7 in urinary bladder cancer predicts time to tumor recurrence. Archives of Medical Science, 2015, 2, 378-384.	0.4	10
18	Prediction of the risk of surgical complications in patients undergoing monopolar transurethral resection of bladder tumour â€“ a prospective multicentre observational study. Archives of Medical Science, 2020, 16, 863-870.	0.4	10

#	Article	IF	Citations
19	The Potential of Asiatic Acid in the Reversion of Cyclophosphamide-Induced Hemorrhagic Cystitis in Rats. International Journal of Molecular Sciences, 2021, 22, 5853.	1.8	10
20	The time from diagnosis of bladder cancer to radical cystectomy in Polish urological centres â€“ results of CysTiming Poland study. Central European Journal of Urology, 2014, 67, 329-32.	0.2	10
21	The Role of Microbial Factors in Prostate Cancer Developmentâ€”An Up-to-Date Review. Journal of Clinical Medicine, 2021, 10, 4772.	1.0	10
22	Complete blood count-derived inflammatory markers and survival in patients with localized renal cell cancer treated with partial or radical nephrectomy: a retrospective single-tertiary-center study. Frontiers in Bioscience - Scholar, 2022, 14, 5.	0.8	10
23	Pathophysiological effect of bladder outlet obstruction on the urothelium. Ultrastructural Pathology, 2018, 42, 317-322.	0.4	8
24	Open partial nephrectomy for entirely intraparenchymal tumors: a matched case-control study of oncologic outcome and complication rate. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 209-215.	0.7	7
25	Catheter-associated bacterial flora in patients with benign prostatic hyperplasia: shift in antimicrobial susceptibility pattern. BMC Infectious Diseases, 2018, 18, 590.	1.3	7
26	Management of Intradiverticular Bladder Tumours: A Systematic Review. Urologia Internationalis, 2020, 104, 42-47.	0.6	7
27	Changing patterns of urologic emergency visits and admissions during the COVID-19 pandemic: a retrospective, multicenter, nationwide study. Archives of Medical Science, 2020, 17, 1262-1276.	0.4	7
28	En-bloc resection of urinary bladder tumour â€“ a prospective controlled multicentre observational study. Wideochirurgia I Inne Techniki Maloinwazyjne, 2021, 16, 145-150.	0.3	7
29	How has the COVID-19 pandemic impacted Polish urologists? Results from a national survey. Central European Journal of Urology, 2020, 73, 252-259.	0.2	7
30	Timing of radical cystectomy in Central Europe - multicenter study on factors influencing the time from diagnosis to radical treatment of bladder cancer patients. Central European Journal of Urology, 2015, 68, 9-14.	0.2	7
31	The View Outside of the Box: Reporting Outcomes Following Radical Cystectomy Using Pentafecta From a Multicenter Retrospective Analysis. Frontiers in Oncology, 2022, 12, 841852.	1.3	7
32	Diagnostic and treatment delays among patients with primary bladder cancer in Poland: a survey study. Central European Journal of Urology, 2020, 73, 152-159.	0.2	6
33	Exogenously administered bombesin and gastrin releasing peptide contract the female rat urethra in vivo and in vitro. Neurourology and Urodynamics, 2011, 30, 1681-1685.	0.8	5
34	Optimum anesthesia for reliable urethral pressure profilometry in female dogs and goats. International Journal of Urology, 2016, 23, 701-705.	0.5	5
35	Surgical treatment for renal masses in the elderly: analysis of oncological, surgical and functional outcomes. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 531-540.	0.7	5
36	Low Lymphocyte-to-Monocyte Ratio Is the Potential Indicator of Worse Overall Survival in Patients with Renal Cell Carcinoma and Venous Tumor Thrombus. Diagnostics, 2021, 11, 2159.	1.3	5

#	Article	IF	Citations
37	Oncological outcomes of high-grade T1 non-muscle-invasive bladder cancer treatment in octogenarians. International Urology and Nephrology, 2021, 53, 1591-1597.	0.6	4
38	Analysis of Clinicopathological Factors Influencing Survival in Patients with Renal Cell Carcinoma and Venous Tumor Thrombus. Journal of Clinical Medicine, 2021, 10, 3852.	1.0	4
39	A prospective, randomized trial comparing the use of KTP (GreenLight) laser versus electroresection-supplemented laser in the treatment of benign prostatic hyperplasia. Central European Journal of Urology, 2016, 69, 391-395.	0.2	4
40	Bimanual palpation for staging of bladder cancer-clinical use and its predictors. Turkish Journal of Urology, 2019, 45, 22-26.	1.3	4
41	Re-innervation pattern of the â€˜neovaginaâ€™ created from the bladder flap in patients with Mayer-Rokitanski-Kistner-Hauser syndrome: An immunochemical study. Gynecological Endocrinology, 2009, 25, 362-371.	0.7	3
42	Anaesthesia of the posterior urethra and pain reduction during cystoscopy â€“ a randomized controlled trial. Wideochirurgia I Inne Techniki Maloinwazyjne, 2017, 1, 75-80.	0.3	3
43	Expression of E-cadherin, Î²-catenin, and epithelial membrane antigen does not predict survival in patients with high-risk non-muscle-invasive bladder cancer. Central-European Journal of Immunology, 2018, 43, 421-427.	0.4	3
44	A systematic review of preventive and therapeutic options for symptoms of cystitis in patients with bladder cancer receiving intravesical bacillus Calmetteâ€“GuÃ©rin immunotherapy. Anti-Cancer Drugs, 2019, 30, 517-522.	0.7	3
45	Bladder perforation during transurethral resection of bladder tumour is not a result of a deficient structure of the bladder wall. World Journal of Surgical Oncology, 2020, 18, 216.	0.8	3
46	Blood count-derived inflammatory markers predict time to Bacillus Calmette-GuÃ©rin failure in high-risk non-muscle-invasive bladder cancer. Archives of Medical Science, 2021, , .	0.4	3
47	Patterns of care in patients with muscle-invasive bladder cancer - a retrospective cohort study. Wspolczesna Onkologia, 2016, 20, 341-3.	0.7	3
48	The Four-Feature Prognostic Models for Cancer-Specific and Overall Survival after Surgery for Localized Clear Cell Renal Cancer: Is There a Place for Inflammatory Markers?. Biomedicines, 2022, 10, 1202.	1.4	3
49	Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-GuÃ©rin for Adjuvant Treatment of Patients with Intermediate- and High-risk Nonâ€“Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046â€“52. European Urology, 2017, 71, e29-e30.	0.9	2
50	Re: Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-GuÃ©rin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-GuÃ©rin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. European Urology, 2019, 75, 879-880.	0.9	2
51	External validation of a magnetic resonance imaging-based algorithm for prediction of side-specific extracapsular extension in prostate cancer. Central European Journal of Urology, 2021, 74, 327-333.	0.2	2
52	Feasibility of active surveillance in small testicular mass: a mini review. Central European Journal of Urology, 2021, 74, 10-13.	0.2	2
53	Factors affecting one-year survival after radical cystectomy: a prospective study. Central European Journal of Urology, 2017, 70, 238-244.	0.2	2
54	The incidence of renal cancer in Polish National Cancer Registry: is there any epidemiological data we can rely on?. Central European Journal of Urology, 2014, 67, 253-6.	0.2	2

#	Article	IF	Citations
55	Recommendations for neurological, obstetrical and gynaecological care in women with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. Neurologia I Neurochirurgia Polska, 2020, 54, 125-137.	0.6	2
56	E-Cadherin, Integrin Alpha2 (Cd49b), and Transferrin Receptor-1 (Tfr1) Are Promising Immunohistochemical Markers of Selected Adverse Pathological Features in Patients Treated with Radical Prostatectomy. Journal of Clinical Medicine, 2021, 10, 5587.	1.0	2
57	Evaluation of PD-L1 (E1L3N, 22C3) expression in venous tumor thrombus is superior to its assessment in renal tumor in predicting overall survival in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	2
58	Not as black as it is painted? The impact of the first wave of COVID-19 pandemic on surgical treatment of urological cancer patients in Poland â€“ a cross-country experience. Archives of Medical Science, 2021, , .	0.4	1
59	A stone pushed back to the collecting system â€“ long therapeutic path in centers with limited access to flexible instruments. Central European Journal of Urology, 2018, 71, 186-189.	0.2	1
60	Re: Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups. European Urology, 2022, 82, 240-241.	0.9	1
61	Availability and Patterns of Intravesical BCG Instillations. Urology Journal, 2017, 14, 5068-5070.	0.3	1
62	Incontinence: Do We Speak the Same Language?. European Urology, 2014, 65, 96-98.	0.9	0
63	Non-invasive evaluation of cardiac index by impedance cardiography in patients undergoing percutaneous nephrolithotomy. Archives of Medical Science, 2018, 14, 801-806.	0.4	0
64	Internal optical urethrotomy is the treatment of choice in stenosis of the bladder neck after open prostate adenectomy. Wideochirurgia I Inne Techniki Maloinwazyjne, 2019, 14, 427-432.	0.3	0
65	Re: A Randomized, Double-blind, Placebo-controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome. European Urology, 2019, 75, 534.	0.9	0
66	Re: Are We Improving Erectile Function Recovery After Radical Prostatectomy? Analysis of Patients Treated over the Last Decade. European Urology, 2019, 75, 534-535.	0.9	0
67	Re: Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9â€“10 Prostate Cancer. European Urology, 2020, 77, 393-394.	0.9	0
68	Human kidney injury molecule-1 as a urine biomarker differentiating urothelial and renal cell carcinoma. Central European Journal of Urology, 2021, 74, 295-299.	0.2	0
69	Editorial comment. Urologia Polska, 2013, 65, 20-21.	0.5	0
70	Letter to the Editor. Central European Journal of Urology, 2014, 67, 116.	0.2	0
71	Extent of lymphadenectomy in patients with bladder cancer undergoing radical cystectomy - a multi-institutional analysis. Central European Journal of Urology, 2016, 69, 323-326.	0.2	0
72	A prospective, randomized trial comparing the use of KTP (GreenLight) laser versus electroresection-supplemented laser in the treatment of benign prostatic hyperplasia AUTHOR'S REPLY. Central European Journal of Urology, 2016, 69, 397.	0.2	0

#	Article	IF	Citations
73	Subinguinal microsurgical varicocelectomy is safe and effective in a solitary testicle. Asian Journal of Andrology, 2020, 22, 120.	0.8	0
74	Urinary Human Kidney Injury Molecule1- (hKIM1-) is not Increased in Patients with Renal Cell Carcinoma. Urology Journal, 2020, 17, 664-666.	0.3	0